{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:30:08Z","timestamp":1792805408904,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This study explored drug repurposing strategies against conserved RNA structures in the SARS-CoV-2 genome to address viral mutation challenges. Conserved RNA elements were computationally identified by aligning 283 SARS-CoV-2 genomes from Korean patients. RNA secondary structures were predicted using RNAfold and RNAstructure, followed by virtual screening of 11 compounds using the RNALigands database (binding energy threshold: -6.0\u00a0kcal\/mol). The antiviral activity and cytotoxicity of riboflavin were experimentally validated in vitro using Vero E6 cells infected with SARS-CoV-2 (MOI 0.01). Riboflavin exhibited selective antiviral activity against SARS-CoV-2 (IC<jats:sub>50<\/jats:sub>\u2009=\u200959.41 \u00b5M), showing no cytotoxicity at concentrations\u2009&lt;\u2009100 \u00b5M. Riboflavin treatment during viral inoculation significantly reduced viral replication, whereas riboflavin treatment pre- or post-inoculation had no effect. The other screened compounds lacked antiviral efficacy. In terms of antiviral activity, riboflavin was less potent than remdesivir (IC<jats:sub>50<\/jats:sub>\u2009=\u200925.81 \u00b5M). Riboflavin is a potential RNA-targeted therapeutic agent against SARS-CoV-2. This study established a framework for integrating computational and experimental methods to identify conserved RNA targets, thus offering a strategy applicable to other RNA viruses. This result indicates the potential of riboflavin as a broad-spectrum antiviral agent against SARS-CoV-2 and highlights the importance of considering nutritional factors in the context of viral infections.<\/jats:p>","DOI":"10.1038\/s41598-025-16949-8","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:36:04Z","timestamp":1755880564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In silico screening and experimental validation identify riboflavin as an RNA-targeted antiviral against SARS-CoV-2"],"prefix":"10.1038","volume":"15","author":[{"given":"Chae-Hong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Jin","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmi","family":"Ryou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"16949_CR1","doi-asserted-by":"publisher","first-page":"704205","DOI":"10.3389\/fphar.2021.704205","volume":"12","author":"C Chakraborty","year":"2021","unstructured":"Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G. & Lee, S. S. The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. Front. Pharmacol. 12, 704205 (2021).","journal-title":"Front. Pharmacol."},{"key":"16949_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discovery. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"16949_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00210-020-01901-6","volume":"393","author":"M Rameshrad","year":"2020","unstructured":"Rameshrad, M., Ghafoori, M., Mohammadpour, A. H., Nayeri, M. J. D. & Hosseinzadeh, H. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). Naunyn Schmiedebergs Arch. Pharmacol. 393, 1137\u20131152. https:\/\/doi.org\/10.1007\/s00210-020-01901-6 (2020).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"16949_CR4","doi-asserted-by":"crossref","unstructured":"Lucaj, T. et al. An overview of the development of pharmacotherapeutics targeting SARS-CoV-2. Drug Discovery Today, 104126 (2024).","DOI":"10.1016\/j.drudis.2024.104126"},{"key":"16949_CR5","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636\u20131643. https:\/\/doi.org\/10.1038\/s41591-020-1051-9 (2020).","journal-title":"Nat. Med."},{"key":"16949_CR6","doi-asserted-by":"publisher","unstructured":"Iserman, C. et al. Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid. Mol Cell 80, 1078\u20131091 e1076, (2020). https:\/\/doi.org\/10.1016\/j.molcel.2020.11.041","DOI":"10.1016\/j.molcel.2020.11.041"},{"key":"16949_CR7","doi-asserted-by":"publisher","first-page":"114367","DOI":"10.1016\/j.biopha.2023.114367","volume":"162","author":"SMR Hashemian","year":"2023","unstructured":"Hashemian, S. M. R. et al. Paxlovid (Nirmatrelvir\/Ritonavir): A new approach to Covid-19 therapy? Biomed. Pharmacother. 162, 114367 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"16949_CR8","unstructured":"Harris, M. & Bagozzi, D. WHO discontinues hydroxychloroquine and lopinavir\/ritonavir treatment arms for COVID-19. World Health Organ. News Release 4 (2020)."},{"key":"16949_CR9","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.bcp.2020.114296","volume":"183","author":"H Yousefi","year":"2021","unstructured":"Yousefi, H., Mashouri, L., Okpechi, S. C., Alahari, N. & Alahari, S. K. Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: A review describing drug mechanisms of action. Biochem. Pharmacol. 183, 114296 (2021).","journal-title":"Biochem. Pharmacol."},{"key":"16949_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2142\/biophysico.bppb-v18.025","volume":"18","author":"A Hijikata","year":"2021","unstructured":"Hijikata, A. et al. Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins. Biophys. Physicobiology. 18, 226\u2013240 (2021).","journal-title":"Biophys. Physicobiology"},{"key":"16949_CR11","doi-asserted-by":"publisher","unstructured":"Rodrigues, L., Cunha, B., Vassilevskaia, R., Viveiros, T., Cunha, C. & M. & Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates. Molecules 27 https:\/\/doi.org\/10.3390\/molecules27092723 (2022).","DOI":"10.3390\/molecules27092723"},{"key":"16949_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43588-020-00007-6","volume":"1","author":"G Galindez","year":"2021","unstructured":"Galindez, G. et al. Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat. Comput. Sci. 1, 33\u201341 (2021).","journal-title":"Nat. Comput. Sci."},{"key":"16949_CR13","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2\u00a0M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593. https:\/\/doi.org\/10.1126\/science.abl4784 (2021).","journal-title":"Science"},{"key":"16949_CR14","doi-asserted-by":"publisher","first-page":"802766","DOI":"10.3389\/fchem.2021.802766","volume":"9","author":"S Hegde","year":"2021","unstructured":"Hegde, S., Tang, Z., Zhao, J. & Wang, J. Inhibition of SARS-CoV-2 by targeting conserved viral RNA structures and sequences. Front. Chem. 9, 802766. https:\/\/doi.org\/10.3389\/fchem.2021.802766 (2021).","journal-title":"Front. Chem."},{"key":"16949_CR15","doi-asserted-by":"crossref","unstructured":"Li, S., Li, H., Lian, R., Xie, J. & Feng, R. New perspective of small-molecule antiviral drugs development for RNA viruses. Virology, 110042 (2024).","DOI":"10.1016\/j.virol.2024.110042"},{"key":"16949_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","volume":"7","author":"S Lei","year":"2022","unstructured":"Lei, S., Chen, X., Wu, J., Duan, X. & Men, K. Small molecules in the treatment of COVID-19. Signal. Transduct. Target. Therapy. 7, 387 (2022).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"16949_CR17","doi-asserted-by":"publisher","first-page":"eabe9403","DOI":"10.1126\/science.abe9403","volume":"370","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370, eabe9403 (2020).","journal-title":"Science"},{"key":"16949_CR18","doi-asserted-by":"publisher","first-page":"15917","DOI":"10.3390\/ijms232415917","volume":"23","author":"M Nalewaj","year":"2022","unstructured":"Nalewaj, M. & Szabat, M. Examples of structural motifs in viral genomes and approaches for RNA structure characterization. Int. J. Mol. Sci. 23, 15917 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"16949_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5483\/BMBRep.2022.55.9.077","volume":"55","author":"HY Jo","year":"2022","unstructured":"Jo, H. Y. et al. Establishment of the large-scale longitudinal multi-omics dataset in COVID-19 patients: data profile and biospecimen. BMB Rep. 55, 465\u2013471. https:\/\/doi.org\/10.5483\/BMBRep.2022.55.9.077 (2022).","journal-title":"BMB Rep."},{"key":"16949_CR20","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N Engl. J. Med."},{"key":"16949_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond, J. et al. Oral nirmatrelvir for High-Risk, nonhospitalized adults with Covid-19. N Engl. J. Med. 386, 1397\u20131408. https:\/\/doi.org\/10.1056\/NEJMoa2118542 (2022).","journal-title":"N Engl. J. Med."},{"key":"16949_CR22","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19 - Final report. N Engl. J. Med. 383, 1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764 (2020).","journal-title":"N Engl. J. Med."},{"key":"16949_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-biodatasci-110123-025333","volume":"7","author":"HC Cousins","year":"2024","unstructured":"Cousins, H. C., Nayar, G. & Altman, R. B. Computational approaches to drug repurposing: methods, challenges, and opportunities. Annu. Rev. Biomed. Data Sci. 7, 15\u201329. https:\/\/doi.org\/10.1146\/annurev-biodatasci-110123-025333 (2024).","journal-title":"Annu. Rev. Biomed. Data Sci."},{"key":"16949_CR24","doi-asserted-by":"publisher","first-page":"e27043","DOI":"10.1016\/j.heliyon.2024.e27043","volume":"10","author":"TK Nguyen","year":"2024","unstructured":"Nguyen, T. K. et al. The therapeutic landscape for COVID-19 and post-COVID-19 medications from genetic profiling of the Vietnamese population and a predictive model of drug-drug interaction for comorbid COVID-19 patients. Heliyon 10, e27043. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27043 (2024).","journal-title":"Heliyon"},{"key":"16949_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1261\/rna.078889.121","volume":"28","author":"S Sun","year":"2022","unstructured":"Sun, S., Yang, J. & Zhang, Z. RNALigands: a database and web server for RNA\u2013ligand interactions. Rna 28, 115\u2013122 (2022).","journal-title":"Rna"},{"key":"16949_CR26","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1017\/S0007114507832971","volume":"98","author":"S Maggini","year":"2007","unstructured":"Maggini, S., Wintergerst, E. S., Beveridge, S. & Hornig, D. H. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br. J. Nutr. 98, S29\u2013S35 (2007).","journal-title":"Br. J. Nutr."},{"key":"16949_CR27","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/ijms21082996","volume":"21","author":"S Zhu","year":"2020","unstructured":"Zhu, S., Rooney, S. & Michlewski, G. RNA-targeted therapies and high-throughput screening methods. Int. J. Mol. Sci. 21, 2996 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"16949_CR28","doi-asserted-by":"publisher","first-page":"36181","DOI":"10.1039\/D1RA05320E","volume":"11","author":"PP Sharma","year":"2021","unstructured":"Sharma, P. P. et al. Computational methods directed towards drug repurposing for COVID-19: advantages and limitations. RSC Adv. 11, 36181\u201336198 (2021).","journal-title":"RSC Adv."},{"key":"16949_CR29","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.2174\/0929867329666220627121416","volume":"29","author":"Y Cetin","year":"2022","unstructured":"Cetin, Y. et al. Review on in Silico methods, high-throughput screening techniques, and cell culture based in vitro assays for SARS-CoV-2. Curr. Med. Chem. 29, 5925\u20135948 (2022).","journal-title":"Curr. Med. Chem."},{"key":"16949_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.27.012906","author":"R Rangan","year":"2020","unstructured":"Rangan, R., Zheludev, I. N. & Das, R. RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses. BioRxiv https:\/\/doi.org\/10.1101\/2020.03.27.012906 (2020).","journal-title":"BioRxiv"},{"key":"16949_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1261\/rna.039834.113","volume":"19","author":"A Philips","year":"2013","unstructured":"Philips, A., Milanowska, K., Lach, G. & Bujnicki, J. M. LigandRNA: computational predictor of RNA-ligand interactions. RNA 19, 1605\u20131616. https:\/\/doi.org\/10.1261\/rna.039834.113 (2013).","journal-title":"RNA"},{"key":"16949_CR32","doi-asserted-by":"publisher","unstructured":"Lorenz, R. et al. ViennaRNA package 2.0. Algorithms Mol. Biol. 6 https:\/\/doi.org\/10.1186\/1748-7188-6-26 (2011).","DOI":"10.1186\/1748-7188-6-26"},{"key":"16949_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-11-129","volume":"11","author":"JS Reuter","year":"2010","unstructured":"Reuter, J. S. & Mathews, D. H. RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinform. 11, 1\u20139 (2010).","journal-title":"BMC Bioinform."},{"key":"16949_CR34","doi-asserted-by":"publisher","first-page":"130582","DOI":"10.1016\/j.bbagen.2024.130582","volume":"1868","author":"RA Akasov","year":"2024","unstructured":"Akasov, R. A. et al. Evaluation of molecular mechanisms of riboflavin anti-COVID-19 action reveals anti-inflammatory efficacy rather than antiviral activity. Biochim. Biophys. Acta Gen. Subj. 1868, 130582. https:\/\/doi.org\/10.1016\/j.bbagen.2024.130582 (2024).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"16949_CR35","doi-asserted-by":"publisher","first-page":"755745","DOI":"10.3389\/fphar.2022.755745","volume":"13","author":"RA Akasov","year":"2022","unstructured":"Akasov, R. A. et al. Riboflavin for COVID-19 adjuvant treatment in patients with mental health disorders: observational study. Front. Pharmacol. 13, 755745. https:\/\/doi.org\/10.3389\/fphar.2022.755745 (2022).","journal-title":"Front. Pharmacol."},{"key":"16949_CR36","doi-asserted-by":"publisher","unstructured":"Suwannasom, N., Kao, I., Pruss, A., Georgieva, R. & Baumler, H. Riboflavin: the health benefits of a forgotten natural vitamin. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21030950 (2020).","DOI":"10.3390\/ijms21030950"},{"key":"16949_CR37","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1021\/ja00109a008","volume":"117","author":"CT Lauhon","year":"1995","unstructured":"Lauhon, C. T. & Szostak, J. W. RNA aptamers that bind flavin and nicotinamide redox cofactors. J. Am. Chem. Soc. 117, 1246\u20131257. https:\/\/doi.org\/10.1021\/ja00109a008 (1995).","journal-title":"J. Am. Chem. Soc."},{"key":"16949_CR38","doi-asserted-by":"publisher","unstructured":"Dricot, C. et al. Riboflavin for women\u2019s health and emerging microbiome strategies. NPJ Biofilms Microbiomes. 10 https:\/\/doi.org\/10.1038\/s41522-024-00579-5 (2024).","DOI":"10.1038\/s41522-024-00579-5"},{"key":"16949_CR39","doi-asserted-by":"publisher","first-page":"19091","DOI":"10.1038\/s41598-020-76251-7","volume":"10","author":"H Ahn","year":"2020","unstructured":"Ahn, H., Lee, G. S. & Riboflavin Vitamin B2, attenuates NLRP3, NLRC4, AIM2, and non-canonical inflammasomes by the Inhibition of caspase-1 activity. Sci. Rep. 10, 19091. https:\/\/doi.org\/10.1038\/s41598-020-76251-7 (2020).","journal-title":"Sci. Rep."},{"key":"16949_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1476-511X-10-177","volume":"10","author":"AA Qureshi","year":"2011","unstructured":"Qureshi, A. A. et al. Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. Lipids Health Dis. 10, 177. https:\/\/doi.org\/10.1186\/1476-511X-10-177 (2011).","journal-title":"Lipids Health Dis."},{"key":"16949_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay, M. Z., Poh, C. M., Renia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363\u2013374. https:\/\/doi.org\/10.1038\/s41577-020-0311-8 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"16949_CR42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu, B., Huang, S. & Yin, L. The cytokine storm and COVID-19. J. Med. Virol. 93, 250\u2013256. https:\/\/doi.org\/10.1002\/jmv.26232 (2021).","journal-title":"J. Med. Virol."},{"key":"16949_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1471-2105-11-129","volume":"11","author":"JS Reuter","year":"2010","unstructured":"Reuter, J. S. & Mathews, D. H. RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinform. 11, 129. https:\/\/doi.org\/10.1186\/1471-2105-11-129 (2010).","journal-title":"BMC Bioinform."},{"key":"16949_CR44","doi-asserted-by":"publisher","unstructured":"Eberle, R. J. et al. Riboflavin, a Potent Neuroprotective Vitamin: Focus on Flavivirus and Alphavirus Proteases. Microorganisms 10, (2022). https:\/\/doi.org\/10.3390\/microorganisms10071331","DOI":"10.3390\/microorganisms10071331"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16949-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16949-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:17:26Z","timestamp":1757416646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16949-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16949"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16949-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"As this study relied on secondary data, no ethical approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"30935"}}